IP Library Granted Patent US 8,802,081
Granted Patent B2
US 8,802,081 · App. 13/807,253 · Granted Aug 12, 2014

Biomatrix scaffolds

Inventors: Yunfang Wang (Beijing, CN); Lola Cynthia McAdams Reid (Chapel Hill, NC); Mitsuo Yamauchi (Chapel Hill, NC); Cai-Bin Cui (Carrboro, NC); Andrew Zhuang Wang (Durham, NC); Michael Edward Werner (Lake Forest, IL)
Assignee: The University of North Carolina at Chapel Hill
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,802,081
App. No.
13/807,253
Granted
Aug 12, 2014
Kind
B2
Abstract

The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same.

Claims (22)

1. A method of producing a biomatrix scaffold from biological tissue, comprising:

a) perfusing or homogenizing biological tissue with a first basal medium, wherein the tissue is selected from the group consisting of liver, lung, thyroid, skin, pancreas, blood vessels, bladder, kidneys, brain, biliary tree, duodenum, abdominal aorta, iliac vein, heart and intestines, and wherein the osmolality of said first medium is from about 250 mOsm/kg to about 350 mOsm/kg and said first medium is serum free and at neutral pH; then

b) perfusing the biological tissue or extracting the homogenate of step (a) with a delipidating buffer comprising lipases and detergents in said first medium, wherein the detergents do not comprise sodium dodecyl sulfate or Triton X-100; then

c) perfusing the tissue or extracting the homogenate of step (b) with a buffer at a neutral pH and comprising a salt concentration from about 2.0M NaCl to about 5.0M, the concentration chosen to keep insoluble collagens identified in the biological tissue; then

d) perfusing the tissue or extracting the homogenate of step (c) with RNase and DNase in a buffer; and then

e) rinsing the tissue or homogenate of step (d) with a second medium that is at neutral pH, is serum-free and has an osomolality from about 250 mOsm/kg to about 350 mOsm/kg,

thereby producing an intact or homogenized biomatrix scaffold from the biological tissue, said biomatrix scaffold comprising at least 95% of the collagens and most collagen-associated matrix components and matrix bound growth factors, hormones and cytokines of the biological tissue.

2. The method of claim 1 , wherein the detergents are selected from the group consisting of salts of deoxycholic acid, 1-heptanesulfonic acid, N-laurylsarcosine, lauryl sulfate, 1-octane sulfonic acid and taurocholic acid; benzalkonium chloride; cetylpyridinium; methylbenzethonium chloride; decamethonium bromide; alkyl betaines; alkyl amidoalkyl betaines; N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate; phosphatidylcholine; n-decyl α-D-glucopyranoside; n-decyl α-D-maltopyranoside; n-dodecyl β-D-maltoside; n-octyl β-D-glucopyranoside; sorbitan esters; n-tetradecyl β-D-maltoside; tritons; Nonidet-P-40; Poloxamer 188; sodium lauryl sulfate; and sodium deoxycholate.

3. The method of claim 1 , wherein the lipases are phospholipases.

4. The method of claim 1 , wherein the basal medium is selected from the group consisting of RPMI 1640, DME/F12, DME, F12, Waymouth's, and William's medium.

5. The method of claim 1 , wherein the second medium comprises at least one of the constituents present in interstitial fluid.

6. The method of claim 1 , wherein the delipidating buffer of step (b) comprises from about 20 units/L to about 50 units/L, phospholipase A2 and about 1% sodium deoxycholate in the first medium.

7. The method of claim 1 , wherein the salt concentration of the buffer of step (c) is from about 3.4M NaCl to about 3.5M NaCl when used for scaffold preparation from an adult liver and is from about 4.0M NaCl to about 4.5M NaCl when used for scaffold preparation from a fetal liver.

8. The method of claim 1 , wherein the buffer of step (c) further comprises a protease inhibitor.

9. The method of claim 8 , wherein the protease inhibitor is soybean trypsin inhibitor.

10. The method of claim 1 , wherein the buffer of step (d) fur comprises a protease inhibitor.

11. The method of claim 10 , wherein the protease inhibitor is soybean trypsin inhibitor.

12. The method claim 1 , wherein all media and buffers of steps (a) through (e) are free of a detectable amount of an enzyme that degrades extracellular matrix components.

13. The method of claim 1 further comprising sterilizing the biomatrix scaffold.

14. The method of claim 13 , wherein the sterilizing step comprises gamma irradiation of the biomatrix scaffold.

15. The method of claim 1 , wherein the biological tissue is selected from the group consisting of liver tissue, lung tissue, pancreatic tissue, thyroid tissue, intestinal tissue, skin tissue, blood vessel tissue, bladder tissue, heart tissue and kidney issue.

16. The method of claim 1 , wherein the biological tissue is from a mammal.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 1, 2013
From: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030744/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2013
From: WANG, YUNFANG; MCADAMS REID, LOLA CYNTHIA; YAMAUCHI, MITSUO; CUI, CAI-BIN; WANG, ANDREW ZHUANG; WERNER, MICHAEL EDWARD
To: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Reel/Frame 029730/0409 →
Continuity (2)
Provisional Application 61360939 · Jul 2, 2010
Related Publication 20130195811A1 · Aug 1, 2013